Lexaria Bioscience says dosing in first human trial of DehydraTECH CBD to treat high blood pressure has started
It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun
Lexaria Bioscience Corp () () revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially underway.
It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun, the company told investors.
READ: Lexaria Bioscience says DehyrdaTECH CBD client's product featured in New Hope Network best of 2020 list
"Dosing is expected to be completed, on schedule, within several weeks, and we may be in a position to report preliminary data in July or thereabouts," said Chris Bunka, Lexaria CEO.
"Despite challenges in launching a human clinical study during a global pandemic, Lexaria’s Europe-based research partners have done an excellent job of balancing the need for scientific validation for a potential new hypertension treatment, with the required safety protocols currently in place."